295 related articles for article (PubMed ID: 7679580)
1. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
2. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
4. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
9. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen in prostatic cancer.
Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
[TBL] [Abstract][Full Text] [Related]
11. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta AM
Tumour Biol; 1996; 17(1):20-6. PubMed ID: 7501969
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
15. Inter-relation between measurement of serum prostatic specific antigen and transrectal ultrasound in the diagnosis of benign prostatic hyperplasia and prostatic cancer.
Clements R; Etherington RJ; Griffiths GJ; Peeling WB; Hughes H; Penney MD
Br J Urol; 1992 Aug; 70(2):183-7. PubMed ID: 1382795
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
Leitenberger A; Altwein JE
Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
[TBL] [Abstract][Full Text] [Related]
17. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
19. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
20. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]